Using apixaban (Eliquis; Bristol-Myers Squibb) for the treatment of atrial fibrillation (AF) is associated with significantly less gastrointestinal bleeding when compared with other direct oral ...
In everyday practice, patients with atrial fibrillation or flutter who are newly started on apixaban (Eliquis; Bristol-Myers Squibb) have lower ischemic and bleeding risks compared with those started ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...
For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...
Please provide your email address to receive an email when new articles are posted on . Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding ...
At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...
With the recent approval of apixaban in most major countries for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), all 3 of the new oral ...
Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been ...
Discover comprehensive details about Apixaban, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback